Angioimmunoblastic T cell lymphoma

Last revised by Yuranga Weerakkody on 26 Jul 2020

Angioimmunoblastic T-cell lymphoma (AITL) (previously known as angioimmunoblastic lymphadenopathy with dysproteinemia (AILD)) is a rare, aggressive (fast-growing) form of peripheral T-cell lymphoma. It only accounts for around 1-2% of all non-Hodgkin lymphoma. It is one of the more common subtypes of mature T-cell lymphomas. 

It is more common in the elderly.

The clinical spectrum includes:

Despite advances in treatment regimens for angioimmunoblastic T cell lymphoma, prognosis remains poor with an overall 5-year median survival of 32% 3.

It was initially described in 1974 by Frizzera et al as angioimmunoblastic lymphadenopathy with dysproteinemia (AILD).

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.